Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.

Nat Commun

Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Published: September 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508237	PMC
http://dx.doi.org/10.1038/s41467-022-33355-0	DOI Listing

Publication Analysis

author correction

correction identification

identification optimal

optimal dosing

dosing schedules

schedules dacomitinib

dacomitinib osimertinib

osimertinib phase

phase i/ii

i/ii trial

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!